Throughout 2023, the life sciences industry has been faced with many operational issues, including supply-chain uncertainty, inflation, and talent shortages.
3SBio will leverage Therapure’s downstream purification expertise to bolster its own biologics portfolio while expanding its contract biomanufacturing business and global presence.
Athenex will invest a minimum of $1.62 bn over the next ten years in labor, materials, and supplies, to create a new manufacturing facility and to expand its North American headquarters.
EMD Millipore’s Massachusetts facilities will now offer upstream capabilities including media and feed screening, small-scale material production, and optimization of conditions for scale-up and technology transfer.
Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.
With the Chinese NAP (nucleic acid purification) market expected to grow more than 8% over the next year and no clear market leaders, companies are looking to take control of the industry space.
In an exclusive Q&A Mark Rohlfing, Almac’s director of Quality, updates Outsourcing-pharma on the firm’s new North American HQ, growth plans and US recruitment drive.
